Agilent Technologies Inc. (A)
NYSE: A
· Real-Time Price · USD
106.61
-0.85 (-0.79%)
At close: Apr 30, 2025, 2:16 PM
Agilent Revenue Breakdown
| Period Ending | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 | Jul 31, 2019 | Apr 30, 2019 | Jan 31, 2019 | Oct 31, 2018 | Jul 31, 2018 | Apr 30, 2018 | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 | Jan 31, 2017 | Oct 31, 2016 | Jul 31, 2016 | Apr 30, 2016 | Jan 31, 2016 | Oct 31, 2015 | Jul 31, 2015 | Apr 30, 2015 | Jan 31, 2015 | Oct 31, 2014 | Jul 31, 2014 | Apr 30, 2014 | Jan 31, 2014 | Oct 31, 2013 | Jul 31, 2013 | Apr 30, 2013 | Jan 31, 2013 | Oct 31, 2012 | Jul 31, 2012 | Apr 30, 2012 | Jan 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab Revenue | 426M | 411M | 402M | 405M | 404M | 396M | 387M | 381M | 381M | 359M | 353M | 359M | 572M | 560M | 536M | 532M | 518M | 463M | 449M | 470M | 476M | 467M | 455M | 442M | 441M | 426M | 426M | 408M | 404M | 386M | 378M | 363M | 370M | 360M | 346M | 344M | 178M | 336M | 321M | 331M | 612M | 592M | 577M | 591M | 1.09B | 163M | 166M | 163M | 296M | 106M | 469M | 461M |
| Agilent CrossLab Revenue Growth | +3.65% | +2.24% | -0.74% | +0.25% | +2.02% | +2.33% | +1.57% | 0.00% | +6.13% | +1.70% | -1.67% | -37.24% | +2.14% | +4.48% | +0.75% | +2.70% | +11.88% | +3.12% | -4.47% | -1.26% | +1.93% | +2.64% | +2.94% | +0.23% | +3.52% | 0.00% | +4.41% | +0.99% | +4.66% | +2.12% | +4.13% | -1.89% | +2.78% | +4.05% | +0.58% | +93.26% | -47.02% | +4.67% | -3.02% | -45.92% | +3.38% | +2.60% | -2.37% | -45.93% | +570.55% | -1.81% | +1.84% | -44.93% | +179.25% | -77.40% | +1.74% | n/a |
| Diagnostics and Genomics Revenue | 442M | 385M | 417M | 407M | 356M | 349M | 362M | 342M | 352M | 340M | 358M | 339M | 341M | 346M | 315M | 294M | 294M | 241M | 263M | 249M | 269M | 263M | 254M | 235M | 302M | 237M | 219M | 185M | 210M | 197M | 201M | 164M | 193M | 180M | 178M | 158M | n/a | 167M | 169M | 148M | n/a | n/a | n/a | n/a | n/a | 401M | 405M | 401M | 261M | 391M | n/a | n/a |
| Diagnostics and Genomics Revenue Growth | +14.81% | -7.67% | +2.46% | +14.33% | +2.01% | -3.59% | +5.85% | -2.84% | +3.53% | -5.03% | +5.60% | -0.59% | -1.45% | +9.84% | +7.14% | 0.00% | +21.99% | -8.37% | +5.62% | -7.43% | +2.28% | +3.54% | +8.09% | -22.19% | +27.43% | +8.22% | +18.38% | -11.90% | +6.60% | -1.99% | +22.56% | -15.03% | +7.22% | +1.12% | +12.66% | n/a | n/a | -1.18% | +14.19% | n/a | n/a | n/a | n/a | n/a | n/a | -0.99% | +1.00% | +53.64% | -33.25% | n/a | n/a | n/a |
| Life Sciences and Applied Markets Revenue | 833M | 782M | 754M | 846M | 928M | 927M | 968M | 1.03B | 1.12B | 1.02B | 896M | 976M | 747M | 680M | 674M | 722M | 671M | 557M | 526M | 638M | 622M | 544M | 529M | 607M | 551M | 540M | 561M | 618M | 575M | 531M | 523M | 540M | 548M | 504M | 495M | 526M | n/a | 511M | 473M | 547M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Life Sciences and Applied Markets Revenue Growth | +6.52% | +3.71% | -10.87% | -8.84% | +0.11% | -4.24% | -6.29% | -7.44% | +9.52% | +13.73% | -8.20% | +30.66% | +9.85% | +0.89% | -6.65% | +7.60% | +20.47% | +5.89% | -17.55% | +2.57% | +14.34% | +2.84% | -12.85% | +10.16% | +2.04% | -3.74% | -9.22% | +7.48% | +8.29% | +1.53% | -3.15% | -1.46% | +8.73% | +1.82% | -5.89% | n/a | n/a | +8.03% | -13.53% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 | Oct 31, 2021 | Oct 31, 2020 | Oct 31, 2019 | Oct 31, 2018 | Oct 31, 2017 | Oct 31, 2016 | Oct 31, 2015 | Oct 31, 2014 | Oct 31, 2013 | Oct 31, 2012 | Oct 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas Revenue | 2.57B | 2.73B | 2.68B | 2.4B | 1.97B | 1.86B | 1.41B | 1.31B | 1.25B | 1.21B | 2.07B | 2.04B | 2.22B | 1.76B |
| Americas Revenue Growth | -5.82% | +1.86% | +11.56% | +22.15% | +5.75% | +31.61% | +7.61% | +5.04% | +3.73% | -41.74% | +1.32% | -7.89% | +26.02% | n/a |
| Asia Pacific Revenue | 2.17B | 2.35B | 2.47B | 2.23B | 1.93B | 1.86B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Asia Pacific Revenue Growth | -7.67% | -4.86% | +10.78% | +15.51% | +3.60% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Europe Revenue | 1.77B | 1.75B | 1.7B | 1.69B | 1.44B | 1.44B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Europe Revenue Growth | +0.91% | +3.24% | +0.65% | +16.98% | +0.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 | Jul 31, 2019 | Apr 30, 2019 | Jan 31, 2019 | Oct 31, 2018 | Jul 31, 2018 | Apr 30, 2018 | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 | Jan 31, 2017 | Oct 31, 2016 | Jul 31, 2016 | Apr 30, 2016 | Jan 31, 2016 | Oct 31, 2015 | Jul 31, 2015 | Apr 30, 2015 | Jan 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 397M | 395M | 380M | 393M | 393M | 407M | 415M | 419M | 422M | 412M | 386M | 417M | 389M | 403M | 420M | 407M | 387M | 347M | 358M | 404M | 385M | 366M | 354M | 355M | 356M | 339M | 338M | 341M | 325M | 308M | 307M | 289M | 321M | 310M | 318M | 304M | 297M | 290M | 292M | 310M |
| Selling, General, and Administrative Revenue Growth | +0.51% | +3.95% | -3.31% | 0.00% | -3.44% | -1.93% | -0.95% | -0.71% | +2.43% | +6.74% | -7.43% | +7.20% | -3.47% | -4.05% | +3.19% | +5.17% | +11.53% | -3.07% | -11.39% | +4.94% | +5.19% | +3.39% | -0.28% | -0.28% | +5.01% | +0.30% | -0.88% | +4.92% | +5.52% | +0.33% | +6.23% | -9.97% | +3.55% | -2.52% | +4.61% | +2.36% | +2.41% | -0.68% | -5.81% | n/a |
| Research and Development Revenue | 111M | 127M | 113M | 120M | 114M | 118M | 126M | 123M | 119M | 116M | 115M | 117M | 116M | 113M | 109M | 103M | 102M | 92M | 197M | 104M | 102M | 101M | 99M | 102M | 104M | 97M | 91M | 93M | 89M | 87M | 84M | 79M | 84M | 86M | 81M | 78M | 82M | 79M | 81M | 88M |
| Research and Development Revenue Growth | -12.60% | +12.39% | -5.83% | +5.26% | -3.39% | -6.35% | +2.44% | +3.36% | +2.59% | +0.87% | -1.71% | +0.86% | +2.65% | +3.67% | +5.83% | +0.98% | +10.87% | -53.30% | +89.42% | +1.96% | +0.99% | +2.02% | -2.94% | -1.92% | +7.22% | +6.59% | -2.15% | +4.49% | +2.30% | +3.57% | +6.33% | -5.95% | -2.33% | +6.17% | +3.85% | -4.88% | +3.80% | -2.47% | -7.95% | n/a |